123 related articles for article (PubMed ID: 8615673)
1. The immunohistochemical expression of cathepsin D in colorectal cancer.
Valentini AM; Pirrelli M; Armentano R; Caruso ML
Anticancer Res; 1996; 16(1):77-80. PubMed ID: 8615673
[TBL] [Abstract][Full Text] [Related]
2. Expression of sialyl lewis X, sialyl Lewis A, E-cadherin and cathepsin-D in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis.
Jeschke U; Mylonas I; Shabani N; Kunert-Keil C; Schindlbeck C; Gerber B; Friese K
Anticancer Res; 2005; 25(3A):1615-22. PubMed ID: 16033070
[TBL] [Abstract][Full Text] [Related]
3. [Cathepsin D expression in primary breast cancer. Comparison of immunohistochemical and biochemical results].
Göhring UJ; Ingenhorst A; Crombach G; Scharl A
Pathologe; 1993 Dec; 14(6):313-7. PubMed ID: 8121884
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical evaluation of cathepsin D expression in colorectal tumours: a correlation with extracellular matrix components, p53, pRb, bcl-2, c-erbB-2, EGFR and proliferation indices.
Ioachim EE; Goussia AC; Machera M; Tsianos EV; Kappas AM; Agnantis NJ
Anticancer Res; 1999; 19(3A):2147-55. PubMed ID: 10470163
[TBL] [Abstract][Full Text] [Related]
5. Expression of cathepsin D and galectin 3 in tubular carcinomas of the breast.
Fernandez-Aguilar S; Noël JC
APMIS; 2008 Jan; 116(1):33-40. PubMed ID: 18254778
[TBL] [Abstract][Full Text] [Related]
6. Cathepsin-D in human breast cancer: correlation with vascular invasion and other clinical and histopathological characteristics.
Hähnel R; Harvey J; Robbins P; Sterrett G
Anticancer Res; 1993; 13(6A):2131-5. PubMed ID: 8297125
[TBL] [Abstract][Full Text] [Related]
7. Expression of E-cadherin, beta-catenin, cathepsin D, gelatinases and their inhibitors in invasive ductal breast carcinomas.
Zhang YG; DU J; Tian XX; Zhong YF; Fang WG
Chin Med J (Engl); 2007 Sep; 120(18):1597-605. PubMed ID: 17908479
[TBL] [Abstract][Full Text] [Related]
8. Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases.
Boonsong A; Curran S; McKay JA; Cassidy J; Murray GI; McLeod HL
Hum Pathol; 2002 Nov; 33(11):1114-9. PubMed ID: 12454816
[TBL] [Abstract][Full Text] [Related]
9. Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors.
Jahkola T; Toivonen T; von Smitten K; Virtanen I; Wasenius VM; Blomqvist C
Br J Cancer; 1999 Apr; 80(1-2):167-74. PubMed ID: 10389993
[TBL] [Abstract][Full Text] [Related]
10. [Expression of cathepsin D in breast cancer and its clinical and histopathological correlations].
Ramírez-Ortega MC; Frías-Mendívil M; Delgado-Chávez R; Meneses-García A; Carrillo-Hernández JF; Ramírez-Ugalde MT; Zeichner-Gancz I
Rev Invest Clin; 1997; 49(5):361-8. PubMed ID: 9527695
[TBL] [Abstract][Full Text] [Related]
11. Cathepsin D and dynamic magnetic resonance imaging gadolinium enhancement in malignant and benign breast lesions.
Stomper PC; Winston JS; Herman S; Klippenstein DL; Blumenson LE
Clin Cancer Res; 1997 Apr; 3(4):559-63. PubMed ID: 9815720
[TBL] [Abstract][Full Text] [Related]
12. Cathepsin D in host stromal cells, but not in tumor cells, is associated with aggressive behavior in node-negative breast cancer.
Nadji M; Fresno M; Nassiri M; Conner G; Herrero A; Morales AR
Hum Pathol; 1996 Sep; 27(9):890-5. PubMed ID: 8816882
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinase expression in human breast cancer: an immunohistochemical study including correlation with cathepsin D, type IV collagen, laminin, fibronectin, EGFR, c-erbB-2 oncoprotein, p53, steroid receptors status and proliferative indices.
Ioachim EE; Athanassiadou SE; Kamina S; Carassavoglou K; Agnantis NJ
Anticancer Res; 1998; 18(3A):1665-70. PubMed ID: 9673387
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
15. [Expression and prognostic relation of cathepsin D in non-small cell lung cancer tissues and lymph nodes].
Wang Z; Zhao X
Zhonghua Jie He He Hu Xi Za Zhi; 1998 Mar; 21(3):164-6. PubMed ID: 11263354
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical p53 overexpression correlated to c-erbB-2 and cathepsin D proteins in colorectal cancer.
Caruso ML; Valentini AM
Anticancer Res; 1996; 16(6B):3813-8. PubMed ID: 9042263
[TBL] [Abstract][Full Text] [Related]
17. Cathepsin-D expression in breast lesion: an immunohistochemical study.
Brujan I; Mărgăritescu C; Simionescu C; Pirici D; Fronie A; Foarfă C; Stepan A; Vrabete M
Rom J Morphol Embryol; 2009; 50(1):31-9. PubMed ID: 19221643
[TBL] [Abstract][Full Text] [Related]
18. Comparative prognostic value of Cathepsin D and urokinase plasminogen activator, detected by immunohistochemistry, in primary breast carcinoma.
Göhring UJ; Scharl A; Thelen U; Ahr A; Crombach G
Anticancer Res; 1996; 16(2):1011-8. PubMed ID: 8687092
[TBL] [Abstract][Full Text] [Related]
19. Biological and clinical significance of cathepsin D in breast cancer.
Rochefort H
Semin Cancer Biol; 1990 Apr; 1(2):153-60. PubMed ID: 2103491
[TBL] [Abstract][Full Text] [Related]
20. Cathepsin D expression in human colorectal cancer: relationship with tumour type and tissue differentiation grade.
Sebzda T; Saleh Y; Gburek J; Andrzejak R; Gnus J; Siewinski M; Grzebieniak Z
J Exp Ther Oncol; 2005; 5(2):145-50. PubMed ID: 16471040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
